An Observational Study on Lecanemab Treatment for Early Alzheimer's Disease

This observational study is tracking how patients with early Alzheimer's disease or mild memory impairment respond to a new medication called lecanemab in real-world clinical practice in China. It is not testing a new drug but observing outcomes in people already receiving lecanemab. **You may be eligible if...** - You are between 45 and 85 years old - You have at least 3 years of education - You have been diagnosed with mild Alzheimer's disease or mild cognitive impairment caused by Alzheimer's - Your brain amyloid PET scan shows significant amyloid plaque buildup - You meet specific memory and function scoring criteria **You may NOT be eligible if...** - You have a history of stroke or significant brain lesions, including more than 5 microscopic bleeds on MRI - You have another neurological condition causing cognitive impairment (e.g., Parkinson's, Huntington's, epilepsy, tumors) - You have systemic conditions causing memory problems (e.g., thyroid disease, vitamin deficiency, HIV, alcohol abuse) - You have serious liver, kidney, lung, heart, or blood problems - You take blood-thinning medications (e.g., warfarin) - You have metal implants that prevent MRI - You refuse to sign consent Talk to your doctor to see if this trial is right for you.